358970-91-9Relevant academic research and scientific papers
Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
-
, (2008/06/13)
The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their us
Pharmaceutical compositions based on azetidine derivatives
-
, (2008/06/13)
A stable pharmaceutical composition comprising at least one azetidine derivative of formula in which Ar is an aromatic or heteroaromatic group optionally substituted with one or more (C1-C4)alkyl, halogen, NO2, CN, (C1-C4)alkoxy or OH groups, optionally in combination with one or more other active ingredients capable of potentiating the effects of the at least one azetidine derivative of formula (Ia) or (Ib), in a system comprising at most 2 principal excipients chosen from nonionic and hydrophilic surfactants capable of solubilizing the at least one azetidine derivative of formula (Ia) or (Ib) and, where appropriate, the one or more active ingredients potentiating the effects of the at least one azetidine derivative, and capable of causing the formation of a colloidal system, optionally supplemented with a second excipient of a lipophilic nature. The pharmaceutical compositions are advantageous because, for example, of the high affinity of the derivatives for cannabinoid receptors.
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
-
, (2008/06/13)
The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions containing, as an active ingredient, at least one compound of formula: in which R1represents a radical —N(R4)R5, —N(R4)—CO—R5, —N(R4)—SO2R6or one of its pharmaceutically acceptable salts, to the novel derivatives of formula (I), to their pharmaceutically acceptable salts and to their preparation.
